Overview
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis
Status:
Completed
Completed
Trial end date:
2020-07-01
2020-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The aim is to examine the expression of αvβ3 integrin using a novel selective radiotracer in patients with myocardial infarction and investigate if it is a suitable tool for predicting myocardial recovery and thus prognosis.Phase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Rigshospitalet, Denmark
Criteria
Inclusion Criteria:- Age over 50 years
Acute myocardial infarction Group:
- Verified first-time acute myocardial infarction treated with PCI
Control Group:
- Previous healthy
- No known cardiac disease
Exclusion Criteria:
- No prior history of acute coronary infarction
- No prior history of Heart surgery
- Not treated with anti-angiogenic medicine
- Subject with pacemaker, cochlear implant or insulin pump
- Pregnancy
- Lactation
- Severe claustrophobia
- Severe obesity (weight above 140kg)
- If a subject is in the fertile age, a pregnancy test will be use prior to injection to
the PET_tracer
- If a subject is having a severe allergic reaction to the PET-tracer, the person will
be excluded for the rest of the trial
- If the PET-tracer is administered subcutaneous, the person will be excluded for the
rest of the trial¨
- Tupe I or II diabetes